OBJECTIVES: To use DNA arrays to identify differences in gene expression associated with relapsing-remitting (RR) MS. METHODS: Total RNA was isolated from monocyte depleted peripheral blood mononuclear cells of 15 RR MS patients and 15 age- and sex-matched controls. The RNA was reverse transcribed to radiolabeled cDNA and the resultant cDNA was used to probe a DNA array containing over 4000 named human genes. The binding of radiolabeled cDNA to the probes on the array was measured by phosphorimager. RESULTS: Of more than 4000 genes tested, only 34 were significantly different in RR-MS patients from controls. Of these, 25 were significantly increased and 9 significantly decreased in the RR MS patients. Twelve of these genes have inflammatory and/or immunological functions that could be relevant to the MS disease process. The potentially relevant genes that were elevated (15% to 28%) were P protein, LCK, cAMP responsive element modulator, IL-7 receptor, matrix metalloproteinase-19, M130 antigen, and peptidyl-prolyl isomerase. Those that were significantly decreased (15% to 35%) were SAS transmembrane 4 superfamily protein, STRL22 (C-C chemokine receptor 6), AFX protein, DNA fragmentation factor-45 and immunoglobulin gamma 3 (Gm marker). CONCLUSIONS: The RR-MS disease effect was relatively restricted and most of the mRNAs tested were not different from the normal controls. However, there were significant differences identified in the expression of a subset of mRNAs, including 13 with inflammatory/immune functions that could be relevant to MS. The systematic use of DNA arrays can provide insight into the dynamic cellular pathways involved in MS pathogenesis and its phenotypic heterogeneity.
OBJECTIVES: To use DNA arrays to identify differences in gene expression associated with relapsing-remitting (RR) MS. METHODS: Total RNA was isolated from monocyte depleted peripheral blood mononuclear cells of 15 RR MS patients and 15 age- and sex-matched controls. The RNA was reverse transcribed to radiolabeled cDNA and the resultant cDNA was used to probe a DNA array containing over 4000 named human genes. The binding of radiolabeled cDNA to the probes on the array was measured by phosphorimager. RESULTS: Of more than 4000 genes tested, only 34 were significantly different in RR-MS patients from controls. Of these, 25 were significantly increased and 9 significantly decreased in the RR MS patients. Twelve of these genes have inflammatory and/or immunological functions that could be relevant to the MS disease process. The potentially relevant genes that were elevated (15% to 28%) were P protein, LCK, cAMP responsive element modulator, IL-7 receptor, matrix metalloproteinase-19, M130 antigen, and peptidyl-prolyl isomerase. Those that were significantly decreased (15% to 35%) were SAS transmembrane 4 superfamily protein, STRL22 (C-C chemokine receptor 6), AFX protein, DNA fragmentation factor-45 and immunoglobulin gamma 3 (Gm marker). CONCLUSIONS: The RR-MS disease effect was relatively restricted and most of the mRNAs tested were not different from the normal controls. However, there were significant differences identified in the expression of a subset of mRNAs, including 13 with inflammatory/immune functions that could be relevant to MS. The systematic use of DNA arrays can provide insight into the dynamic cellular pathways involved in MS pathogenesis and its phenotypic heterogeneity.
Authors: Ludwig Kappos; Lutz Achtnichts; Frank Dahlke; Jens Kuhle; Y Naegelin; Rupert Sandbrink; Raija L P Lindberg Journal: J Neurol Date: 2005-09 Impact factor: 4.849
Authors: Tong Liu; K Christian Donahue; Jun Hu; Michael P Kurnellas; Jennifer E Grant; Hong Li; Stella Elkabes Journal: J Proteome Res Date: 2007-06-16 Impact factor: 4.466
Authors: Connie S Chamberlain; Sabrina H Brounts; David G Sterken; Kevin I Rolnick; Geoffrey S Baer; Ray Vanderby Journal: J Appl Physiol (1985) Date: 2011-05-19
Authors: Dorothee Nickles; Hsuan P Chen; Michael M Li; Pouya Khankhanian; Lohith Madireddy; Stacy J Caillier; Adam Santaniello; Bruce A C Cree; Daniel Pelletier; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini Journal: Hum Mol Genet Date: 2013-06-06 Impact factor: 6.150
Authors: D R Booth; A T Arthur; S M Teutsch; C Bye; J Rubio; P J Armati; J D Pollard; R N S Heard; G J Stewart Journal: J Mol Med (Berl) Date: 2005-08-02 Impact factor: 4.599
Authors: Jessica J Ashbaugh; Roberta Brambilla; Shaffiat A Karmally; Cecilia Cabello; Thomas R Malek; John R Bethea Journal: J Immunol Date: 2013-03-25 Impact factor: 5.422
Authors: David Otaegui; Sergio E Baranzini; Ruben Armañanzas; Borja Calvo; Maider Muñoz-Culla; Puya Khankhanian; Iñaki Inza; Jose A Lozano; Tamara Castillo-Triviño; Ana Asensio; Javier Olaskoaga; Adolfo López de Munain Journal: PLoS One Date: 2009-07-20 Impact factor: 3.240